Analysts Cut Targets as Healthpeak Shorts Retreat

DOC heads into its November 2 earnings report with short sellers pulling back sharply even as analysts trim their price targets, a divergence that frames the key tension for this print.

Short interest has fallen 12% over the past week and 14% over the past month, leaving bears holding just 3.1% of the free float as of October 28. The retreat has been steady: positions peaked around 28 million shares in mid-October before dropping to roughly 21.4 million. Borrow conditions are exceptionally loose, with availability at nearly 3,100% of current short interest, meaning there is no meaningful constraint on either adding or covering positions. Cost to borrow ticked up 17% on the week to 0.46%, but that remains a negligible level by any measure. Options positioning is modestly more cautious than usual, with the put/call ratio at 0.45 versus a 20-day average of 0.41, though the z-score of 0.94 puts this well within normal range.

The analyst community has moved in a consistent direction ahead of the print: target prices are coming down. Wells Fargo cut its target from $22 to $19 on October 19, while Barclays dropped from $24 to $21 on October 13 and UBS trimmed from $21.50 to $20. None of these moves came with a rating change; all three maintained neutral or equal-weight stances. The mean target across the Street is now $22.39, implying around 18% upside to the current price of $18.94. The bear case centres on lab tenant credit risk and weak leasing, with revised FFOPS growth of just 1% CAGR through 2027. The bull case points to a 700-property portfolio with $148 million in new development projects roughly 80% pre-leased and targeted mid-7% yields on stabilisation, a pipeline that could support a re-rating if occupancy trends stabilise.

The stock is down 5.8% over the past month and off 2.1% on the week, underperforming several peers: HR gained 1.1% on the week and OHI added 1.2%, though ARE fell 6.3%, suggesting broader life-science REIT pressure is a factor rather than DOC-specific weakness alone. Wikipedia attention has risen sharply, with an attention z-score of 2.44 against DOC's own 90-day history as of October 22, pointing to a pickup in retail interest around this name ahead of the report. The earnings print will test whether lab occupancy and leasing trends justify the Street's recently compressed targets or whether the development pipeline provides enough forward visibility to stabilise the discount.